A compound of Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein: the dashed line indicates a double bond; A is N or CR 5, wherein R 5 is hydrogen or C 1 -C 3 -alkyl; R 2 and R 3 are each, independently, selected from the group consisting of hydrogen, hydroxyl, C 1 -C 3 -alkyl, C 3 -C 8 -cycloalkyl, heterocyclyl, aryl, heteroaryl, substituted C 1 -C 3 -alkyl, substituted C 3 -C 8 -cycloalkyl, substituted heterocyclyl, substituted aryl and substituted heteroaryl; R 4 is selected from the group consisting of C (CH 2 CH 3) 2, C (CH 2 CH 3)Ph, CH 2 CH 3, cyclopropyl, cyclopentyl or cyclohexyl; X is N or CR 11, and Y is CR 12; R 11 is selected from the group consisting of halo, hydrogen, C 1 -C 3 -alkyl, C 1 -C 3 -alkoxy, CN, C=NOH, C=NOCH 3, C H, C C 1 -C 3 -alkyl, C 3 -C 8 -cycloalkyl, heterocyclyl, aryl, heteroaryl, substituted C 1 -C 3 -alkyl, substituted C 3 -C 8 -cycloalkyl, substituted heterocyclyl, substituted aryl, substituted heteroaryl, - BNR 13 R 14, -BOR 13, -BC R 13, -BC OR 13, -BC NR 13 R 14; wherein B is a bond, C 1 -C 3 -alkyl or branched C 1 -C 3 -alkyl; wherein R 13 and R 14 are each, independently, selected from the group consisting of hydrogen, C 1 -C 3 -alkyl, C 3 -C 8 -cycloalkyl, heterocyclyl, aryl, heteroaryl, substituted alkyl, substituted cycloalkyl, substituted heterocyclyl, substituted aryl, and substituted heteroaryl and R 12 is -BC NR 13 R 14; wherein B is a bond, C 1 -C 3 -alkyl or branched C 1 -C 3 -alkyl; wherein R 13 and R 14 are each, independently, selected from the group consisting of hydrogen, C 1 -C 3 -allcyl, C 3 -C 8 -cycloalkyl, heterocyclyl, aryl, heteroaryl, substituted alkyl, substituted cycloalkyl, substituted heterocyclyl, substituted aryl, and substituted heteroaryl. the dashed line indicates a double bond; A is N or CR 5, wherein R 5 is hydrogen or C 1 -C 3 -alkyl; R 2 and R 3 are each, independently, selected from the group consisting of hydrogen, hydroxyl, C 1 -C 3 -alkyl, C 3 -C 8 -cycloalkyl, heterocyclyl, aryl, heteroaryl, substituted C 1 -C 3 -alkyl, substituted C 3 -C 8 -cycloalkyl, substituted heterocyclyl, substituted aryl and substituted heteroaryl; R 4 is selected from the group consisting of C (CH 2 CH 3) 2, C (CH 2 CH 3)Ph, CH 2 CH 3, cyclopropyl, cyclopentyl or cyclohexyl; X is N or CR 11, and Y is CR 12; R 11 is selected from the group consisting of halo, hydrogen, C 1 -C 3 -alkyl, C 1 -C 3 -alkoxy, CN, C=NOH, C=NOCH 3, C H, C C 1 -C 3 -alkyl, C 3 -C 8 -cycloalkyl, heterocyclyl, aryl, heteroaryl, substituted C 1 -C 3 -alkyl, substituted C 3 -C 8 -cycloalkyl, substituted heterocyclyl, substituted aryl, substituted heteroaryl, - BNR 13 R 14, -BOR 13, -BC R 13, -BC OR 13, -BC NR 13 R 14; wherein B is a bond, C 1 -C 3 -alkyl or branched C 1 -C 3 -alkyl; wherein R 13 and R 14 are each, independently, selected from the group consisting of hydrogen, C 1 -C 3 -alkyl, C 3 -C 8 -cycloalkyl, heterocyclyl, aryl, heteroaryl, substituted alkyl, substituted cycloalkyl, substituted heterocyclyl, substituted aryl, and substituted heteroaryl and R 12 is -BC NR 13 R 14; wherein B is a bond, C 1 -C 3 -alkyl or branched C 1 -C 3 -alkyl; wherein R 13 and R 14 are each, independently, selected from the group consisting of hydrogen, C 1 -C 3 -allcyl, C 3 -C 8 -cycloalkyl, heterocyclyl, aryl, heteroaryl, substituted alkyl, substituted cycloalkyl, substituted heterocyclyl, substituted aryl, and substituted heteroaryl.